Gatifloxacin: A review of its use in the treatment of bacterial infections in the US

Drugs

Volumn 65, Issue 5, 2005, Pages 695-724

  Keam, Susan J ^a   Croom, Katherine F ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; AMOXICILLIN PLUS CLAVULANIC ACID; ANTACID AGENT; BETA LACTAMASE; CEFTRIAXONE; CEFUROXIME AXETIL; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; DIGOXIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GATIFLOXACIN; GEMIFLOXACIN; GLIBENCLAMIDE; IRON; LEVOFLOXACIN; MACROLIDE; MAGNESIUM; MIDAZOLAM; MOXIFLOXACIN; OFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN; ZINC;

ABDOMINAL PAIN; ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIABETIC COMA; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; FEMALE; GASTROINTESTINAL SYMPTOM; GONORRHEA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HEADACHE; HEART VENTRICLE ARRHYTHMIA; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; KLEBSIELLA; LIVER TOXICITY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NAUSEA; NEISSERIA GONORRHOEAE; PENICILLIN RESISTANCE; PHOTOTOXICITY; PROTEUS MIRABILIS; PSEUDOMEMBRANOUS COLITIS; PYELONEPHRITIS; QT PROLONGATION; REVIEW; SIDE EFFECT; SINUSITIS; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION; TASTE DISORDER; TENDINITIS; TENDON RUPTURE; TORSADE DES POINTES; UNITED STATES; URINARY TRACT INFECTION; VAGINITIS; VOMITING;

BACTERIAL INFECTIONS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; UNITED STATES;

BACTERIA (MICROORGANISMS); CHLAMYDIA; ENTEROBACTER; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; KLEBSIELLA; LEGIONELLA; MIRABILIS; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NEGIBACTERIA; NEISSERIA GONORRHOEAE; POSIBACTERIA; PROTEUS MIRABILIS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 16644385983     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565050-00007     Document Type: Review

References (150)

1. Perry CM, Ormrod D, Hurst M, et al. Gatifloxacin: a review of its use in the management of bacterial infections. Drugs 2002; 62 (1): 169-207
2. Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 2003 Nov; 37 (9): 1210-5
3. Bristol-Myers Squibb Company, Princeton, New Jersey, USA. Tequin® (gatifloxacin) prescribing information. 2004 Nov [online]. Available from URL: http://www.tequin.com [Accessed 2004 Nov 30]
4. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. Wayne (PA): Clinical and Laboratory Standards Institute, 2005 Jan. Report no: M100-S15 (M7)
5. Sahm DF, Weaver MK, Flamm RK, et al. Rates of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States: results from the TRUST 7 (2002-2003) Surveillance Study [abstract no. 201 plus poster]. 41st Annual Meeting of the Infectious Diseases Society of America; 2003 Oct 9-12; San Diego, 63
6. Low DE, de Azavedo J, Weiss K, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002 May; 46 (5): 1295-301
7. Powis J, McGeer A, Green K, et al. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother 2004; 48 (9): 3305-11
8. Hoban DJ, Biedenbach DJ, Mutnick AH, et al. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 2003 Apr; 45 (4): 279-85
9. Brown SD, Rybak MJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influeniae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. J Antimicrob Chemother 2004; 54 Suppl. S1: i7-i15
10. Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001 May 15; 32 Suppl. 2: S81-93
11. Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003 Jun; 47 (6): 1867-74
12. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect 2004; 48 (1): 56-65
13. Karlowsky JA, Kelly LJ, Thornsberry C, et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Int J Antimicrob Agents 2002 Jan; 19: 21-31
14. Dawis MA, Isenberg HD, France KA, et al. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. J Antimicrob Chemother 2003 May; 51 (5): 1203-11
15. Gordon KA, Beach ML, Biedenbach DJ, et al. Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002 Jun; 43 (2): 157-62
16. Pfaller MA, Ehrhardt AF, Jones RN. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the Respiratory Surveillance Program study: microbiology from the medical office practice environment. Am J Med 2001 Dec 17; 111 (9A): 4S-12S
17. Johnson DM, Sader HS, Fritsche TR, et al. Susceptibility trends of Haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003; 47: 373-6
18. Goldstein EJC, Citron DM, Merriam CV, et al. In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis. Antimicrob Agents Chemother 2003; 47 (6): 1963-7
19. Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47 (6): 1875-81
20. Rennie RP, Jones RN, Mutnick AH. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003; 45 (4): 287-93
21. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001 May 15; 32 Suppl. 2: S114-32
22. Mathai D, Lewis MT, Kugler KC, et al. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I - results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). Diagn Microbiol Infect Dis 2001 Feb; 39 (2): 105-16
23. Mathai D, Jones RN, Pfaller MA, et al. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn Microbiol Infect Dis 2001 Jul; 40 (3): 129-36
24. Thornsberry C, Karlowsky JA, Weaver MK, et al. Current view of antimicrobial susceptibility among common Gram-Negative pathogens: 2003 TRUST Surveillance Study [abstract no. 222 plus poster]. 41st Annual Meeting of the Infectious Diseases Society of America; 2003 Oct 9-12; San Diego, 68
25. Peric M, Jacobs MR, Appelbaum PC. Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents. Antimicrob Agents Chemother 2004 Aug; 48 (8): 3188-92
26. Ednie LM, Rattan A, Jacobs MR, et al. Antianaerobe activity of RBX 7644 (Ranbezolid), a new oxazolidinone, compared with those of eight other agents. Antimicrob Agents Chemother 2003 Mar; 47 (3): 1143-7
27. Sader HS, Huynh HK, Jones RN. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and β-lactams tested against gram-negative bacilli. Diagn Microbiol Infect Dis 2003; 47: 547-50
28. Fung-Tomc J, Minassian B, Kolek B, et al. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000; 45: 437-46
29. Rhomberg PR, Biedenbach DJ, Jones RN. Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp. Diagn Microbiol Infect Dis 2001; 40: 45-9
30. Waites KB, Crabb DM, Duffy LB. Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae. Int J Antimicrob Agents 2003 Jun; 21 (6): 574-7
31. White RL, Enzweiler KA, Friedrich LV, et al. Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000. Diagn Microbiol Infect Dis 2002 Jul; 43: 207-17
32. Biedenbach DJ, Beach ML, Jones RN. Antimicrobial activity of gatifloxacin tested against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolone-resistant strains. Diagn Microbiol Infect Dis 1998; 32: 307-11
33. Roblin PM, Hammerschlag MR. In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae. J Antimicrob Chemother 1999; 44: 549-51
34. Meagher AK, Craing WA, Jones RN, et al. Monte Carlo simulation (MCS) to estimate in vitro susceptibility breakpoints (BPs) for moxifloxacin (M), gatifloxacin (G) and levifloxacin (L) against Staphylococcus aureus (SA) [abstract no. A-136]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC, 11
35. Clark C, Kosowska K, Bozdogan B, et al. In vitro selection of resistance in Haemophilus influenzae by 4 quinolones and 5 β-lactams. Diagn Microbiol Infect Dis 2004 May; 49 (1): 31-6
36. Pendland SL, Neuhauser MM, Garey KW, et al. Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical isolates: impact of bacterial strain and antibiotic concentration. Diagn Microbiol Infect Dis 2002 Sep; 44: 59-61
37. Blondeau JM, Borsos S, Hesje C, et al. The killing of multidrug resistant Streptococcus pneumoniae (MDRSP) by gatifloxacin (GA), gemifloxacin (GM), levofloxacin (Lfx) and moxifloxacin (Mfx) over a range of bacterial inoculums using 2 different drug concentrations [abstract no. 629 plus poster]. World conference on magic bullets: celebrating Paul Ehrlich's 150th birthday; 2004 Sep 9-11; Nürnberg
38. Stein GE, Schooley S, Tyrrell KL, et al. Bactericidal activities of methoxyfluroroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum. Antimicrob Agents Chemother 2003 Apr; 47 (4): 1308-12
39. Blondeau JM, Hansen G, Metzler K, et al. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 2004 Jun; 16 Suppl. 3: 1-19
40. Stein GE, Schooley S. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers. Int J Antimicrob Agents 2004 Aug; 24 (2): 168-72
41. Wise R, Andrews JM. The bactericidal activity of gatifloxacin in plasma and urine. Clin Microbiol Infect 1998 Jul; 4 (7): 392-6
42. Boy D, Well M, Kinzig-Schippers M, et al. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. Int J Antimicrob Agents 2004 Mar; 23 Suppl. 1: S6-S16
43. Pankuch GA, Jacobs MR, Appelbaum PC. Postantibiotic effects of gatifloxacin against Gram-positive and -negative organisms. Antimicrob Agents Chemother 1999; 43 (10): 2574-5
44. Schmitz F-J, Higgins PG, Mayer S, et al. Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance. Eur J Clin Microbiol Infect Dis 2002; 21 (9): 647-59
45. Jacobs MR, Anon J, Appelbaum PC. Mechanisms of resistance among respiratory tract pathogens. Clin Lab Med 2004; 24 (2): 419-53
46. Piddock LJV, Johnson MM, Simjee S, et al. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and - susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46 (3): 808-12
47. Zhanel GG, Walkty A, Nichol K, et al. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn Microbiol Infect Dis 2003 Jan; 45 (1): 63-7
48. Ince D, Hooper DC. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob Agents Chemother 2001 Oct; 45 (10): 2755-64
49. Kishii R, Takei M, Fukuda H, et al. Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae. Antimicrob Agents Chemother 2003 Jan; 47 (1): 77-81
50. Browne FA, Clark C, Bozdogan B, et al. Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin. Int J Antimicrob Agents 2002 Aug; 20: 93-9
51. Pfaller MA, Jones RN. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. Diagn Microbiol Infect Dis 2002 Sep; 44: 77-84
52. Brueggemann AB, Coffman SL, Rhomberg P, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 2002 Mar; 46 (3): 680-8
53. Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US - an update. Clin Infect Dis 2004; 39 Suppl. 3: S142-50
54. Appelbaum PC. Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin Infect Dis 2002 Jun 15; 34 (12): 1613-20
55. Jones RN, Biedenbach DJ, Beach ML. Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003 May; 46 (1): 77-80
56. Brown SD, Farrell DJ. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002. J Antimicrob Chemother 2004; 54 Suppl. S1: i23-9
57. Powis J, Fuller J, Vanderkooi O, et al. Lower levels of in vitro nonsusceptibility to moxifloxacin compared with other fluoroquinolones in Canadian clinical isolates of Streptococcus pneumoniae [abstract no. P1702]. Clin Microbiol Infect 2004 May; 10 Suppl. 3: 482
58. Smith HJ, Nichol KA, Palatnick L, et al. In vitro activity of ABT-492 against ciprofloxacin-resistant Streptococcus pneumoniae (CR SPN) compared to eight other drugs [abstract no. F549 plus poster]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego, 184
59. Jorgensen JH, Weigel LM, Swenson JM, et al. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44 (11): 2962-8
60. Davies TA, Goldschmidt R, Pfleger S, et al. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J Antimicrob Chemother 2003 Aug; 52 (2): 168-75
61. Smith HJ, Walters M, Hisanaga T, et al. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother 2004 Oct; 48 (10): 3954-8
62. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance program, 1999-2000. Clin Infect Dis 2002; 34 Suppl. 1: S4-16
63. Selman LJ, Mayfield DC, Thornsberry C, et al. Changes in single- and multiple-drug resistance among Streptococcus pneumoniae over three years (1997-2000) [abstract no. 1789]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 108
64. Metzler K, Hansen GM, Hedlin P, et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents 2004 Aug; 24 (2): 161-7
65. Biedenbach DJ, Jones RN. Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America). Diagn Microbiol Infect Dis 2000 Apr; 36: 255-9
66. Thornsberry C, Sahm DF, Weaver MK, et al. Antimicrobial susceptibilities of common pathogens causing nosocomial pneumonia: 2001-2003 TRUST surveillance [abstract no. E-2187 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago, 216
67. Weigel LM, Anderson GJ, Tenover FC. DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis. Antimicrob Agents Chemother 2002 Aug; 46 (8): 2582-7
68. Nicolau DP, Ambrose PG. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. Am J Med 2001 Dec 17; 111 (9A): 13S-8S
69. Lister PD. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication. Antimicrob Agents Chemother 2002 Jan; 46 (1): 69-74
70. Firsov AA, Vostrov SN, Lubenko IY, et al. Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination. Int J Antimicrob Agents 2004 Jan; 23 (1): 60-6
71. Ebisu H, Kishii R, Takei M, et al. The effect of pharmacokinetic/ pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae. J Infect Chemother 2003 Sep; 9 (3): 210-4
72. Zhanel GG, Roberts D, Waltky A, et al. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2002 May; 49 (5): 807-12
73. Jones RN, Rubino CM, Bhavnani SM, et al. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother 2003 Jan; 47 (1): 292-6
74. Ambrose PG, Bhavnani SM, Owens Jr RC. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003; 17 (3): 529-43
75. Dalhoff A, Schmitz F-J. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 2003 Apr; 22 (4): 203-21
76. Ambrose PG, Anon JB, Owen JS, et al. Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. Clin Infect Dis 2004 Jun 1; 38 (11): 1513-20
77. Trampuz A, Laifer G, Wenk M, et al. Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate. Antimicrob Agents Chemother 2002 Nov; 46 (11): 3630-3
78. Kang J, Wang L, Chen X-L, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59 (1): 122-6
79. Anderson ME, Mazur A, Yang T, et al. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 2001; 296 (3): 806-10
80. Akita M, Shibazaki Y, Izumi M, et al. Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J Toxicol Sci 2004 Feb; 29 (1): 63-71
81. Gajjar DA, LaCreta FP, Kollia GD, et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 2000 Jun; 20 (6 Pt 2): 76S-86S
82. Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001 Oct; 21 (10 Pt 2): 233S-52S
83. Nakashima M, Uematsu T, Kosuge K, et al. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995 Dec; 39 (12): 2635-40
84. Stahlberg H-J, Goehler K, Guillaume M, et al. Single dose pharmacokinetics of the R- and S-enantiomers of gatifloxacin in volunteers. Drugs 1999; 58 Suppl. 2: 222-4
85. Gajjar DA, LaCreta FP, Uderman HD, et al. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 2000 Jun; 20 (6 Pt 2): 49S-58S
86. Wise R, Andrews JM, Ashby JP, et al. A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose. J Antimicrob Chemother 1999 Nov; 44 (5): 701-4
87. Lober S, Ziege S, Rau M, et al. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Antimicrob Agents Chemother 1999 May; 43 (5): 1067-71
88. LaCreta FP, Kollia GD, Duncan G, et al. Age and gender effects on the pharmacokinetics of gatifloxacin. Pharmacotherapy 2000 Jun; 20 (6 Pt 2): 67S-75S
89. LaCreta FP, Kaul S, Kollia GD, et al. Interchangeability of 400mg intravenous and oral gatifloxacin in healthy adults. Pharmacotherapy 2000 Jun; 20 (6 Pt 2): 59S-66S
90. Mignot A, Guillaume M, Brault M, et al. Multiple-dose pharmacokinetics and excretion balance of gatifloxacin, a new fluoroquinolone antibiotic, following oral administration to healthy Caucasian volunteers. Chemotherapy 2002 Jul; 48: 116-21
91. Lubasch A, Keller I, Borner K, et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000 Oct; 44 (10): 2600-3
92. Mignot A, Guillaume M, Göhler K, et al. Oral bioavailability of gatifloxacin in healthy volunteers under fasting and fed conditions. Chemotherapy 2002 Jul; 48: 111-5
93. Baba S, Suzuki K, Ichikawa G, et al. Pharmacokinetic and clinical studies of gatifloxacin on otorhinolaryngological infections [in Japanese]. Jpn J Chemother 1999 Oct; 47 (10): 632-48
94. Honeybourne D, Wise R, Stahlberg H-J, et al. Tissue penetration of gatifloxacin into bronchial mucosa (BM), epithelial lining fluid (ELF) and alveolar macrophages (AMS) after administration of a single 400mg oral dose [abstract no. 248]. Antiinfect Drugs Chemother 2000; 17 (1): 87
95. Saito A, Nakayama I, Ohmichi M, et al. Early phase II clinical study of gatifloxacin, an oral new quinolone, for infections in the field of internal medicine [in Japanese]. Jpn J Chemother 1999 Sep; 47 Suppl. 2: 260-76
96. Saito A, Ohmichi M, Arakawa M, et al. Late phase-II clinical study of gatifloxacin, an oral new quinolone, in respiratory tract infections [in Japanese]. Jpn J Chemother 1999 Sep; 47 Suppl. 2: 277-91
97. Watanabe H, Masaki H, Watanabe K, et al. Clinical evaluation of gatifloxacin, a new fluoroquinolone, in chronic respiratory tract infections: it's penetration into sputum and bactericidal effect [in Japanese]. Jpn J Chemother 1999 Oct; 47 (10): 623-31
98. Matsuda S, Ando S, Chimura T, et al. Genital tissue penetration and clinical evaluation of gatifloxacin, a new fluoroquinolone, in obstetrics and gynecology [in Japanese]. Jpn J Chemother 1999 Dec; 47 (12): 829-42
99. Tsugawa M, Monden K, Kumon H, et al. Clinical study of gatifloxacin in prostatitis [in Japanese]. Jpn J Chemother 1999 Dec; 47 (12): 843-51
100. Naber CK, Steghafner M, Kinzig-Schippers M, et al. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Antimicrob Agents Chemother 2001 Jan; 45 (1): 293-7
101. Stahlberg HJ, Gohler K, Leclerc V, et al. The effect of varying degrees of renal impairment on the pharmacokinetics and safety of gatifloxacin [abstract no. 195]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 11
102. Kawada Y, Kanimoto Y, Takahashi Y, et al. Pharmacokinetics of gatifloxacin in patients with impaired renal function [in Japanese]. Jpn J Chemother 1999 Sep; 47 Suppl. 2: 238-47
103. Aoki N, Shiba K. Pharmacokinetics of gatifloxacin, a new quinolone, in elderly patients [in Japanese]. Jpn J Chemother 1999 Sep; 47 Suppl. 2: 230-7
104. Grasela DM, Christofalo B, Kollia GD, et al. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment. Pharmacotherapy 2000 Jun; 20 (6 Pt 2): 87S-94S
105. Grasela T, Cirincione B, Christofalo B, et al. Population pharmacokinetics (PPK) of gatifloxacin in adults with acute bacterial exacerbation of chronic bronchitis (ABECB) [abstract no. A-28]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego, 9
106. Olsen SJ, Uderman HD. Pharmacokinetics (PK) of concomitantly administered gatifloxacin and digoxin [abstract no. 199]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 12
107. Kays MB, Overholser BR, Lagvankar S, et al. Effect of Ensure on the oral bioavailability of gatifloxacin [abstract no. A-1626]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago, 39
108. Grant EM, Nicolau DP, Nightingale C, et al. Minimal interaction between gatifloxacin and oxycodone. J Clin Pharmacol 2002 Aug; 42: 928-32
109. Ramirez JA, Nguyen T-H, Tellier G, et al. Treating community-acquired pneumonia with once-daily gatilfoxacin vs twice-daily clarithromycin. J Respir Dis 1999 Nov; 20 (11 Suppl.): S40-8
110. Solèr M, Lode H, Baldwin R, et al. Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic bronchitis. Eur J Clin Microbiol Infect Dis 2003 Mar; 22: 144-50
111. Naber KG, Allin DM, Clarysse L, et al. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. Int J Antimicrob Agents 2004 Jun; 23 (6): 596-605
112. Gotfried M, Quinn TC, Gothelf S, et al. Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study. Diagn Microbiol Infect Dis 2002 Sep; 44: 85-91
113. Nicholson SC, Wilson WR, Naughton BJ, et al. Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2002 Sep; 44: 117-25
114. Sher LD, Poole MD, Von Seggern K, et al. Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin. Otolaryngol Head Neck Surg 2002 Sep; 127 (3): 182-9
115. Cox CC, Marbury TC, Pittman WG, et al. A multicenter comparison of gatifloxacin (GAT) 400mg QD vs. ciprofloxacin (CIP) 500mg BID in the treatment of complicated urinary tract infection (UTI) and pyelonephritis [abstract no. 612]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco, 665
116. Fogarty C, Dowell ME, Ellison WT, et al. Treating community-acquired pneumonia in hospitalized patients: gatifloxacin vs ceftriaxone/clarithromycin. J Respir Dis 1999 Nov; 20 (11 Suppl.): S60-9
117. Sullivan JG, McElroy AD, Honsinger RW, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin. J Respir Dis 1999 Nov; 20 (11 Suppl.): S49-59
118. Gotfried MH, DeAbate CA, Fogarty C, et al. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin Ther 2001; 23 (1): 97-107
119. Fogarty C, McAdoo MA, Zorba Paster R, et al. Gatifloxacin vs clarithromycin in the management of acute sinusitis. J Respir Dis 1999 Nov; 20 (11 Suppl.): S17-22
120. Sher LD, McAdoo MA, Bettis RB, et al. A multicenter, randomized, investigator-blinded study of 5- and 10-day gatifloxacin versus 10-day amoxicillin/clavulanate in patients with acute bacterial sinusitis. Clin Ther 2002; 24 (2): 269-81
121. Richard GA, Mathew CP, Kirstein JM, et al. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology 2002 Mar; 59 (3): 334-9
122. Cox CE, Marbury TC, Pittman WG, et al. A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. Clin Ther 2002; 24 (2): 223-36
123. Stoner BP, Douglas JM, Martin DH, et al. Single-dose gatifloxacin compared with ofloxacin for the treatment of uncomplicated gonorrhea: a randomized, double-blind trial. Sex Transm Dis 2001 Mar; 28 (3): 136-42
124. Tarshis GA, Miskin BM, Jones TM, et al. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother 2001 Aug; 45 (8): 2358-62
125. Von Seggern K., Russo R, Wikler MA. A novel approach to postmarketing surveillance: the Tequin Clinical Experience Study [poster no. 2216]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco
126. Nicholson SC, High KP, Gothelf S, et al. Gatifloxacin in community-based
127. Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone. J Respir Dis 1999 Nov; 20 (11 Suppl.): S70-6
128. Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 2003; 51 Suppl. 1: 21-7
129. Frothingham R. Rates of Torsades de Pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001 Dec; 21 (12): 1468-72
130. Bertino Jr JS, Owens Jr RC, Carnes TD, et al. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 2002 Mar 15; 34: 861-3
131. Nicholson WJ, Buxton AE, Tammaro D. Bradycardic syncope in 2 patients who recently began gatifloxacin treatment. Clin Infect Dis 2003 Feb 1; 36: e35-9
132. Tailor SAN, Simor AE, Cornish W, et al. Analysis of spontaneous reports of hypoglycemia and hyperglycemia associated with marketed systemic fluoroquinolones made to the Canadian Adverse Drug Reaction Monitoring Program. Can J Hosp Pharm 2004 Feb; 57 (1): 12-7
133. Biggs WS. Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients. J Am Board Fam Pract 2003; 16 (5): 455-7
134. LeBlanc M, Bélanger C, Cossette P. Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy. Pharmacotherapy 2004 Jul; 24 (7): 926-31
135. Orlander JD, Serrao R. Gatifloxacin-induced hyperglycemia. Infect Dis Clin Pract 2004 Jul; 12 (4): 230-2
136. Henann NE, Zambie MF. Gatifloxacin-associated acute hepatitis. Pharmacotherapy 2001 Dec; 21 (12): 1579-82
137. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004 Mar 1; 38 (5): 640-5
138. Mohr J. Outbreak of Clostridium difficile infection and gatifloxacin use in a long-term care facility [letter]. Clin Infect Dis 2004; 39: 875-6
139. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003 Dec 1; 37 (11): 1405-33
140. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54
141. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130 (1 Suppl.): 1-45
142. Brook I, Gooch WM, Reiner SA, et al. Medical management of acute bacterial sinusitis: recommendations of a clinical advisory committee on pediatric and adult sinusitis. Ann Otol Rhinol Laryngol 2000; 109: 1-20
143. Snow V, Mottur-Pilson C, Hickner JM. Principles of appropriate antibiotic use for acute sinusitis in adults. Ann Intern Med 2001 Mar 20; 134 (6): 495-7
144. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23 (6): 932-46
145. Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women: Infectious Diseases Society of America. Clin Infect Dis 1999 Oct; 29 (4): 745-58
146. Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines 2002. MMWR 2002 May 10; 51 (No. RR-6) [online]. Available from URL: www.cdc.gov/mmwr [Accessed 2005 Jan 10]
147. Blondeau JM. The role of fluoroquinolones in skin and skin structure infections. Am J Clin Dermatol 2002; 3 (1): 37-46
148. Bayer Pharmaceuticals Corporation. Avelox® (moxifloxacin hydrochloride) tablets. Avelox® I.V. (moxifloxacin hydrochloride in sodium chloride injection) prescribing information. 2004 Oct [online]. Available from URL: http://www.avelox-usa.com [Accessed 2005 Jan 17]
149. Oscient Pharmaceuticals. Factive® (gemifloxacin mesylate) tablets prescribing information. 2004 Feb [online]. Available from URL: http://www.oscient.com [Accessed 2005 Jan 17]
150. Pelly L. IV-to-oral switch therapy for community-acquired pneumonia requiring hospitalization: focus on gatifloxacin. Adv Ther 2002; 19 (5): 229-42